Publications by authors named "Jing-Qiu Yu"
Article Synopsis
- * A clinical trial of ssCAR-T-19 cells, which include shRNA targeting IL-6, involved 61 patients; 52 achieved complete remission while CRS occurred in about 82% of participants, with varying severity levels.
- * Factors like high disease burden and poor genetic risk were linked to a higher chance of severe CRS, and those experiencing severe cases had more severe toxicities and greater expansions of the CAR-T cells post-infusion.
Background: Activating mutations in FMS-like tyrosine kinase 3 (FLT3) are frequent in acute myeloid leukemia (AML) and have important prognostic and therapeutic implications. FLT3 aberrations have been detected in a smaller fraction of acute lymphoblastic leukemia (ALL), and their prognostic value is not well established. We therefore assessed the FLT3 mutation in Chinese adolescent and adult ALL patients.
View Article and Find Full Text PDFThe Role of FLT3-ITD Mutation on de Novo MDS in Chinese Population.
Clin Lymphoma Myeloma Leuk
February 2019
Background: FLT3 mutations have been well-studied in acute myeloid leukemia (AML), and the detection of the FLT3 gene has become a clinical routine. However, it has not been fully analyzed in other hematologic malignancies, such as myelodysplastic syndromes (MDS).
Materials And Methods: Between 2010 and 2016, 304 adult patients with de novo MDS had the FLT3 sequence tested on their bone marrow sample.